# NF-κB Inhibition in Amyotrophic Lateral Sclerosis

> **NCT05031351** · PHASE2 · UNKNOWN · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 75 (estimated)

## Conditions studied

- ALS

## Interventions

- **DRUG:** Withania somnifera
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05031351
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-19
- **Primary completion:** 2022-07
- **Final completion:** 2022-09
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031351, "NF-κB Inhibition in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05031351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*